Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 6/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | PTAFR | P25105 | 6/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.42 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20777174 | 1.00 | GPR132 (0.51) | GPR132NAMPTPLGPTAFRGRIA1 | |
| SCHEMBL20777169 | 0.90 | CTSL (0.49) | CTSLCTSSPIN1 | |
| SCHEMBL20777203 | 0.87 | NAMPT (0.51) | GPR132NAMPTPTAFRCTSLCTSS | |
| SCHEMBL22802202 | 0.87 | NAMPT (0.51) | GPR132NAMPTPTAFRCTSLCTSS | |
| SCHEMBL20777175 | 0.83 | CTSL (0.47) | GPR132GRIA1CTSLCTSSPIN1 | |
| SCHEMBL22822786 | 0.83 | NPC1 (0.48) | CTSL | |
| SCHEMBL22823038 | 0.83 | CTSL (0.47) | GPR132GRIA1CTSLCTSSPIN1 | |
| SCHEMBL20777178 | 0.82 | CTSL (0.52) | GRIA1CTSLCTSSPIN1HDAC8 | |
| SCHEMBL20777202 | 0.82 | CTSL (0.52) | GRIA1CTSLCTSSPIN1HDAC8 | |
| SCHEMBL20777199 | 0.82 | CTSL (0.52) | GRIA1CTSLCTSSPIN1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371406-B2 | Dual acting FKBP12 and FKBP52 inhibitors | PLEX PHARMACEUTICALS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12065407-B2 | Dual acting FKBP12 and FKBP52 inhibitors | PLEX PHARMACEUTICALS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20210395203-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | PLEX PHARMACEUTICALS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210395203-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | PLEX PHARMACEUTICALS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20200399219-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | PLEX PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
| US-20200399219-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | PLEX PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399219-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | FKBP2, FKBP1B, FKBP1A | GPR132 2215/4885NAMPT 2597/4885PLG 4480/4885 |
| US-20210395203-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | FKBP2, FKBP1B, FKBP1A | GPR132 2215/4885NAMPT 2597/4885PLG 4480/4885 |
| US-12065407-B2 | Dual acting FKBP12 and FKBP52 inhibitors | FKBP2, FKBP1B, FKBP1A | GPR132 2215/4885NAMPT 2597/4885PLG 4480/4885 |
| US-12371406-B2 | Dual acting FKBP12 and FKBP52 inhibitors | FKBP2, FKBP1B, FKBP1A | GPR132 2215/4885NAMPT 2597/4885PLG 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.